BRIEF-Monte Rosa Therapeutics Announces First Subjects Dosed In Phase 1 Study Of Mrt-8102, A Nek7-Directed Molecular Glue Degrader For The Treatment Of Multiple Inflammatory Diseases

Reuters
21 Jul
BRIEF-<a href="https://laohu8.com/S/GLUE">Monte Rosa Therapeutics</a> Announces First Subjects Dosed In Phase 1 Study Of Mrt-8102, A Nek7-Directed Molecular Glue Degrader For The Treatment Of Multiple Inflammatory Diseases

July 21 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:

  • MONTE ROSA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 STUDY OF MRT-8102, A NEK7-DIRECTED MOLECULAR GLUE DEGRADER FOR THE TREATMENT OF MULTIPLE INFLAMMATORY DISEASES

  • MONTE ROSA THERAPEUTICS INC - INITIAL RESULTS FROM PHASE 1 STUDY EXPECTED IN H1 2026

  • MONTE ROSA THERAPEUTICS INC: MRT-8102 PHASE 1 STUDY INITIAL RESULTS ANTICIPATED IN H1 2026

Source text: ID:nGNX9VlSGt

Further company coverage: GLUE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10